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Abstract
As part of large on-going vaccine impact studies in Fiji and Mongolia, we identified 25/2750
(0.9%) of nasopharyngeal swabs by microarray that were positive for Streptococcus pneu-
moniae contained pneumococci with a divergent 33F capsular polysaccharide locus
(designated ‘33F-1’). We investigated the 33F-1 capsular polysaccharide locus to better
understand the genetic variation and its potential impact on serotyping results. Whole
genome sequencing was conducted on ten 33F-1 pneumococcal isolates. Initially,
sequence reads were used for molecular serotyping by PneumoCaT. Phenotypic typing of
33F-1 isolates was then performed using the Quellung reaction and latex agglutination.
Genome assemblies were used in phylogenetic analyses of each gene in the capsular locus
to investigate genetic divergence. All ten pneumococcal isolates with the 33F-1 cps locus
typed as 33F by Quellung and latex agglutination. Unlike the reference 33F capsule locus
sequence, DNA microarray and PneumoCaT analyses found that 33F-1 pneumococci lack
the wcjE gene, and instead contain wcyO with a frameshift mutation. Phylogenetic analyses
found the wzg, wzh, wzd, wze, wchA, wciG and glf genes in the 33F-1 cps locus had higher
DNA sequence similarity to homologues from other serotypes than to the 33F reference
sequence. We have discovered a novel genetic variant of serotype 33F, which lacks wcjE
and contains a wcyO pseudogene. This finding adds to the understanding of molecular epi-
demiology of pneumococcal serotype diversity, which is poorly understood in low and mid-
dle-income countries.
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Introduction
Streptococcus pneumoniae (the pneumococcus) is a Gram-positive pathogenic bacterium and a
leading cause of community-acquired pneumonia [1]. Pneumococci are classified by serotype,
defined by an antigenically-distinct polysaccharide capsule. Capsule biosynthesis is encoded
by the capsular polysaccharide (cps) locus within the pneumococcal genome. High levels of
genetic diversity within this locus has resulted in over 90 pneumococcal serotypes described to
date.
The pneumococcal capsule is the target for currently licensed vaccines, which only include
a subset of serotypes. Although pneumococcal conjugate vaccines (PCVs) have been successful
in reducing carriage and disease caused by the targeted serotypes, a rise in carriage and disease
caused by serotypes not included in these vaccines is commonly observed (serotype replace-
ment) [2,3]. To precisely monitor vaccine impact and disease surveillance, accurate tools for
pneumococcal serotyping are required.
Molecular approaches to serotyping pneumococci rely on existing knowledge of cps loci.
Data on pneumococcal cps loci from low- and middle-income countries (LMICs) are relatively
limited, which can impact serotyping results. For example, we recently described a novel
genetic variant of pneumococcal serotype 11A in Fiji. Genetically, the cps locus of these isolates
is most closely related to the 11F cps locus, with only a few minor nucleotide changes resulting
in the production of 11A capsule [4].
Among the replacing serotypes post-PCV introduction, serotype 33F has become a concern
world-wide. Serotype 33F is commonly reported among the predominant serotypes not
included in PCVs causing invasive disease following vaccine introduction [5–7]. The increased
invasive disease caused by serotype 33F has warranted its inclusion in two new vaccine formu-
lations, which are in development by Merck [8]. In this study, we describe a novel 33F cps
locus identified in Fiji and Mongolia by investigating the genetic basis of the variation in this
locus and the potential impact this may have on serotyping results.
Materials and methods
Nasopharyngeal swab collection and screening for pneumococci
As part of ongoing programs in the Asia-Pacific region measuring pneumococcal vaccine
impact, nasopharyngeal swabs from healthy participants in Fiji, and children diagnosed with
pneumonia in Mongolia were collected in accordance with WHO recommendations [9]. Ethi-
cal approval for the study in Fiji was granted from the Fiji National Research ethics review
committee and The University of Melbourne Human research ethics committee. Ethical
approval for the study in Mongolia was granted from the ethics committee associated with The
Ministry of Health in Mongolia and the Royal Children’s Hospital in Melbourne. Written con-
sent for study participants was provided by parents/guardians. Following collection, the swabs
were placed in 1 ml skim milk, tryptone, glucose, and glycerol media [10] and stored at -80˚C.
Samples were screened for the presence of pneumococci by conducting quantitative PCR
(qPCR) on DNA extracted from 100 μl aliquots of the swabs using the pneumococcal lytA
gene as a target as previously described [11].
Molecular serotyping by microarray
Molecular serotyping of pneumococci was performed by DNA microarray. An aliquot of the
nasopharyngeal swab was inoculated onto Horse Blood Agar supplemented with gentamicin
(5 μg/ml), to select for pneumococci, and incubated overnight at 37˚C with 5% CO2. For plates
with α-hemolytic growth, the bacterial growth was collected using 1 ml PBS, pelleted by
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centrifugation and stored at -30˚C. DNA was extracted from thawed bacterial pellets using the
QIAcube HT with the QIAamp 96 DNA QIAcube HT Kit (Qiagen) with the inclusion of a
pre-treatment lysis step whereby 180 μl lysis buffer (20 mM TrisHCl, 2 mM EDTA, 1% Triton
X-100, 2 mg/ml RNase A, 20 mg/ml lysozyme) was added to the bacterial pellet and incubated
at 37ºC for 60 min. The remaining extraction procedure was as per the manufacturer’s instruc-
tions. This DNA was then used for microarray as described previously [12]. In brief, 200 ng of
DNA was labelled with Cy3 or Cy5 using the Genomic DNA ULS Labeling Kit (Agilent Tech-
nologies) and incubated at 85˚C for 30 min. The labelled pneumococcal DNA was incubated
with Senti-SPv1.5 microarray slides (BUGS Bioscience) overnight at 65˚C rotating at 20 rpm.
Microarray slides were washed, scanned, and analyzed using the Agilent microarray scanner
and feature extraction software. Serotype calls were analyzed by Senti-NET software (BUGS
Bioscience) using Bayesian-based algorithms.
Bacterial isolates
The S. pneumoniae isolates used in this study were purified from ten nasopharyngeal swabs
containing 33F-1 from Fiji and Mongolia on selective media as described above. Isolates were
confirmed as S. pneumoniae with microarray and whole genome sequencing.
Whole genome sequencing and molecular typing
For whole genome sequencing, DNA was extracted from pure cultures using the Wizard SV
genomic DNA purification system (Promega) with some modifications. Briefly, pneumococcal
cultures were pre-treated with a lysis solution containing 5 mM EDTA, 3 mg/ml lysozyme and
37.5 μg/ml mutanolysin in TE buffer and incubated at 37˚C for 2 h. Proteinase K was added to
a final concentration of 1 mg/ml and samples were incubated at 55˚C for 1 h. Following incu-
bation, 200 μl of nuclear lysis buffer and 5 μl of RNase (final concentration of 40 μg/ml) were
added and samples were incubated at 80˚C for 10 min. The remaining extraction procedure
was performed as per the manufacturer’s instructions. Eluted DNA was sequenced in 2 x 300
bp paired end reads on the MiSeq platform. Using the Geneious 11.0.4 software package [13],
sequence reads were trimmed with BBDuk and de novo assembled using SPAdes. The capsule
loci were annotated within Geneious using a database consisting of capsule loci from the 90
serotypes described by Bentley et al. [14]. Sequence reads were also used for molecular typing
with PneumoCaT [15].
Sequence analysis
Pairwise alignments were using either MUSCLE or Clustal Omega. Phylogenetic analyses were
performed for each 33F-1 cps gene using MEGA 7 [16]. For each gene, the phylogenetic analy-
sis included a representative 33F-1 sequence as well as homologues from all other serotypes
containing that gene as described by Bentley et al. [14], where Genbank accession numbers are
provided. DNA sequences were aligned using MUSCLE and the alignments were used to gen-
erate maximum likelihood trees based on the Tamura-Nei model. Phylogenetic relationships
were statistically analyzed by bootstrapping (1000 replicates). The 33F-1 cps loci have been
deposited in Genbank (accession no. MH256127, MH256128, MH256129, MH256130,
MH256131, MH256132, MH256133, MH256134, MH256135, MH256136).
Quellung and latex agglutination serotyping
Quellung serotyping was performed as described previously [17]. A saline suspension of pneu-
mococci was prepared from an overnight culture. Using an inoculation loop, 1 μl was placed
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on a microscope slide and mixed with 1 μl of antisera from the Statens Serum Institut (SSI)
(http://www.ssi.dk/ssidiagnostica). The sample was then viewed under the microscope (x400
magnification). A positive reaction was defined as an enlargement or ‘swelling’ of cells, with
serotype call based on the reaction profile with each typing sera. For latex agglutination, latex
reagents were prepared with SSI typing sera [18] and testing performed as previously described
[19]. The bacterial suspension and latex reagent (10 μl of each) were mixed on a glass slide.
The slide was then incubated on an orbital shaker for 2 min at ~140 rpm. A positive reaction
was defined by the presence of visible agglutination. The SSI factor sera used for serotyping of
33F-1 and 33F strains were 33b, 33e, 33f, 6a and 20b.
Results
In our studies evaluating pneumococcal vaccine impact in Fiji and Mongolia, we have used
DNA microarray as a molecular approach to serotype pneumococci contained within naso-
pharyngeal swabs. DNA microarray uses 15,000 oligonucleotides that are spotted onto glass
slides and recognize each capsule gene from the 90+ serotypes. Labelled pneumococcal DNA
is allowed to hybridize to the oligonucleotides so that pneumococcal serotype can be inferred.
From 2750 swabs that contained pneumococci 25 (0.9%) contained pneumococci that typed as
‘33F-like’ (hereby referred to as ‘33F-1’). Ten of these samples were selected and the 33F-1
pneumococci were isolated for further analysis (Table 1).
Compared to the expected results for serotype 33F, microarray reported the wciG, glf and
wcjE genes in the nasopharyngeal swabs containing these isolates as ‘absent/divergent’. In
addition, the wcyO gene was also detected, which has not been reported in the serotype 33F cps
locus previously. To investigate the impact of the divergent 33F-1 cps locus on other molecular
approaches to serotyping, we sequenced the genomes of all ten isolates and ran the sequence
reads through the PneumoCaT pipeline [15]. PneumoCaT uses wcjE to differentiate 33A from
33F, as this gene contains a frameshift mutation in 33F, resulting in a lack of WcjE-mediated
O-acetylation of the 33F capsular polysaccharide [20]. Consistent with microarray, Pneumo-
CaT typed all isolates as 33F and was unable to detect wcjE. Phenotypic serotyping methods
(Quellung and latex agglutination) also typed these isolates as 33F (S1 Table and S1 Fig).
Following investigation of the 33F-1 cps locus, it was evident that not only did all ten iso-
lates lack wcjE, the locus contained wcyO at this position. The wcyO gene encodes an acetyl-
transferase and mediates the same modification as wcjE (6-O-acetylation of galactose) [21].
Table 1. Pneumococcal 33F-1 isolates used in this study.
MLST
Isolate Source Country of isolation aroE ddl gdh gki recP spi xpt Sequence type
PMP1348 Nasopharynx of healthy child (2–7 years old) Fiji 2 18 5 23 18 42 3 13802a
PMP1349 Nasopharynx of healthy child (5–8 weeks old) Fiji 2 18 5 23 18 42 3 13802a
PMP1351 Nasopharynx of healthy child (12–23 months old) Fiji 2 18 5 23 18 42 3 13802a
PMP1352 Nasopharynx of healthy child (12–23 months old) Fiji 2 18 5 23 18 42 3 13802a
PMP1353 Nasopharynx of healthy child (5–8 weeks old) Fiji 2 18 5 23 18 42 3 13802a
PMP1379 Nasopharynx of healthy child (12–23 months old) Fiji 2 18 5 23 18 42 3 13802a
PMP1380 Nasopharynx of healthy child (12–23 months old) Fiji 2 18 5 23 18 42 3 13802a
PMP1383 Nasopharynx of healthy adult Fiji 2 18 5 23 18 42 3 13802a
PMP1386 Nasopharynx of child with pneumonia Mongolia 2 18 5 29 16 42 3 673
PMP1387 Nasopharynx of child with pneumonia Mongolia 2 18 5 29 16 42 3 673
aNovel sequence type identified in this study.
https://doi.org/10.1371/journal.pone.0206622.t001
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The wcyO open reading frame from all 33F-1 isolates contained a frameshift mutation. The
wcyO gene in 33F-1 pneumococci from Fiji had a single T insertion whereas this gene in iso-
lates from Mongolia contained a single A deletion (Fig 1). These frameshift mutations were
also confirmed by Sanger sequencing and were not present in traditional wcyO-containing iso-
lates (serotypes 34 and 39) from Fiji (S2 Fig).
In addition to the differences in wcjE and wcyO, microarray detected some divergence in
other genes in the 33F-1 cps locus compared to the reference 33F sequence. To gain a better
understanding of the relationships of the 33F-1 cps genes to homologues from other serotypes
we performed phylogenetic analyses for each gene. In support of the pairwise alignments (S2
Table), the 33F-1 wciB, wciD, wciE, wciF, wzy and wzx genes clustered with 37/33A/33F
sequences (Fig 2F and 2G and Fig 3A–3D). In contrast, 33F-1 wzg, wzh, wzd, wze and wchA
clustered with serotype 33B sequences (Fig 2A–2E), wciG with serotype 37 (Fig 3E), glf with
serotypes 34 and 39 (Fig 3F) and wcyO with 33C, 34 and 39 (Fig 3G). All branches had strong
statistical support (>85% bootstrap score from 1000 replicates for all genes, except wze with a
67% bootstrap score for the 33F-1/33B branch).
Discussion
Pneumococcus is a highly successful pathogen, in part due to the high level of capsule diversity,
resulting in over 90 serotypes each with unique antigenic properties. Even small differences in
the cps locus can have biologically relevant consequences. Serotypes 33F and 33A have the
same cps locus, except that 33F has a wcjE gene containing a frameshift mutation rendering it
non-functional [22]. Using DNA microarray, we identified a high degree of genetic divergence
Fig 1. Comparison of the wcyO open reading frames of 33F-1 sequences to a representative serotype 34 sequence.
Only a selected portion of the DNA sequence is shown. Numbers refer to the position number in the serotype 34
sequence with an in-frame wcyO gene.
https://doi.org/10.1371/journal.pone.0206622.g001
A novel pneumococcal serotype 33F capsule locus
PLOS ONE | https://doi.org/10.1371/journal.pone.0206622 November 5, 2018 5 / 12
A novel pneumococcal serotype 33F capsule locus
PLOS ONE | https://doi.org/10.1371/journal.pone.0206622 November 5, 2018 6 / 12
in the capsule DNA sequence of some serotypes in Fiji and Mongolia. We characterized a sero-
type 33F variant (33F-1) that has the same genes as the canonical 33F and 33A cps loci, except
it possesses wcyO instead of wcjE. Interestingly, in the 33F-1 variants wcyO is predicted to
encode a truncated protein due to a frameshift mutation. These frameshift mutations suggest a
loss of 6-O-acetylation in 33F-1 capsular polysaccharide as the truncated protein would
unlikely be functional. Interestingly, the same variant has been simultaneously identified in
the Global Pneumococcal Sequencing Project in other countries (van Tonder et al, unpub-
lished), demonstrating 33F-1 pneumococci are not restricted to Fiji and Mongolia.
Although Quellung and latex agglutination serotyping supports the notion that the 33F-1
cps locus encodes a 33F capsule, it is important to note that sera used in these methods are
polyclonal and there is potential for closely related serotypes to cross-react. In addition, the
sera may not recognize all relevant epitopes in the capsule. Although there is no genetic differ-
ence that would result in an obvious antigenic change and no serological differences were
detected in our study, we cannot eliminate the possibility that differences between 33F and
33F-1 capsules exist. Pairwise alignment of the amino acid sequences of 33F and 33F-1 capsu-
lar biosynthesis proteins showed high levels of similarity (over 96% identity for all proteins)
(S3 Fig). The exceptions were the divergent WciG (85.2% identity) and Glf (94.6% identity).
Despite reduced amino acid similarity of the 33F-1 WciG and Glf proteins to 33F homologues,
we hypothesise that they would likely mediate the same modifications. This is supported in
other serotypes where these enzymes have similar levels of variation but still perform the same
function [14,20].
The frameshift mutations in isolates from Fiji and Mongolia have both occurred within
homopolymeric regions (Fig 1 and S2 Fig). Such regions are prone to slipped-strand mispair-
ing, whereby errors made during DNA replication can result in the insertion or deletion of a
nucleotide [23]. We postulate that the frameshift mutations in the 33F-1 wcyO genes are the
result of slipped-strand mispairing events.
This is the first report identifying the wcyO acetyltransferase gene in the 33F cps locus, and
it is also the first report of a naturally occurring frameshifted allele of wcyO. The fact that the
mutation type and location differ between isolates from Fiji and Mongolia demonstrates this
mutation event has occurred on at least two independent occasions. Whether the mutation of
wcyO is due to selective pressure to inactivate a disadvantageous gene or due to a lack of selec-
tive advantage to maintain it remains to be investigated. Previously, mutations have been iden-
tified in other pneumococcal capsule acetyltransferase genes including wciG [24] and wcjE
[22,25,26]. Serotype 11E, which lacks WcjE-mediated acetylation can evade opsonophagocyto-
sis more efficiently compared to 11A (which possess WcjE-mediated acetylation) [25]. Pneu-
mococci expressing 33F capsules, which lack WcjE-mediated acetylation, exhibit enhanced
survival during drying compared to serotype 33A (with intact WcjE-mediated acetylation)
[27]. Laboratory constructed wciG mutants in serogroup 33 isolates were more susceptible to
opsonophagocytosis, and displayed increased adherence and biofilm formation [27]. It is plau-
sible that mutation of wcyO in the 33F-1 pneumococci may serve a similar purpose, however
this requires further investigation.
Fig 2. Maximum likelihood phylogenetic trees of 33F-1 cps genes (wzg-wciD) with homologues from all other
serotypes. As all genes except wchA were identical in all 33F-1 isolates only one sequence is included as a
representative. Un-collapsed trees are provided in S5 Fig. Tree for wciC is not shown as this gene is only present in
serotypes 33F, 33A and 37, which all have over 98% DNA sequence identity to the 33F-1 sequence. DNA sequences
were aligned using MUSCLE and trees were constructed using the Tamura-Nei model in MEGA 7. Only bootstrap
values above 50% are shown.
https://doi.org/10.1371/journal.pone.0206622.g002
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Within the 33F-1 cps locus we identified 7/15 genes that exhibit higher DNA sequence similar-
ity to homologues from other serotypes rather than 33F. Both glf and wcyO are similar to
sequences from serotypes 34 and 39 (and 33C for wcyO) (Fig 3F and 3G) and wzg, wzh, wzd, wze
and wchA similar to sequences from 33B (Fig 2A–2E). Recombination of the pneumococcal cap-
sule genes resulting in mosaic cps loci such as that of 33F-1 have been reported previously [28,29].
Alignment of the 33F and 33F-1 cps loci support this by showing higher sequence divergence
across the wzg through to the 5’ half of wchA, as well as in the second half of wciG and the 5’and 3’
ends of glf, suggesting these may be the recombination sites (S4 Fig). Although it is difficult to
infer the direction of horizontal transfer of these genes, the mosaic nature of the 33F-1 cps locus
would suggest an ancestral 33A/F cps locus was the recipient of these genes. The 33F-1 isolates in
our study were either MLST ST673 or ST13802 (Table 1). Interrogation of the PubMLST database
(as of 16th September 2018) shows that ST673 is primarily associated with serotypes 33A/F and
not in any wcyO-associated serotypes. Likewise, although ST13802 is a novel sequence type
described in this study, the most similar MLST profiles (five or more allele matches to ST13802)
were either 33A/F serotypes or serotypes that do not possess wcyO. These data support the notion
that the ancestral strain(s) from which the 33F-1 cps locus arose likely possessed a 33A/F cps locus.
However, it is important to note that the reverse scenario (a wcyO-associated serotype acquiring
33A/F cps genes) is possible and further genetic analyses are needed.
Interestingly, a serogroup 33 related cps locus has been identified in Streptococcus oralis
subsp. tigurinus strain Az_3a [30]. This cps locus possessed the same genes as the 33F-1 locus
with variable DNA identity (<77% with the 33F-1 wzg, wzh, wzd, wze, wchA and wciB genes,
>96% for wciC, wciD, wciE, wciF and wzy genes, and 85–90% for wzx, wciG and glf genes, S2
Table). The higher DNA identity of 33F-1 cps genes with homologues from other pneumococ-
cal serotypes suggests the Az_3a cps locus may have evolved independently of the 33F-1 locus.
In contrast to 33F-1, the wcyO gene in Az_3a is in frame and most similar to the pneumococcal
serotype 21 homologue (DNA identity 86.8% with serotype 21 wcyO compared to 74.5% with
33F-1 wcyO). The existence of a divergent 33F-1 cps locus with a functional wcyO raises inter-
esting questions around why this gene has been inactivated in 33F-1 pneumococci but remains
intact in a non-pneumococcal streptococcal species.
This study describes a novel genetic basis for pneumococcal serotype 33F. Serotype 33F is a
replacing serotype in invasive disease following vaccine introduction [5–7]. The public health
importance of 33F is reflected in that it has been included in two upcoming vaccine formula-
tions (PCV15 and PCV24) [8]. In addition, there is increasing popularity in molecular serotyp-
ing approaches and it is therefore important to identify genetic variants, which have the
potential to impact serotyping results. This is particularly important for the implementation of
such methods in LMICs, where there is limited understanding of the pneumococcal cps loci.
The data gained from this study will be used to update genetic typing tools for more accurate
typing of serotype 33F in LMICs.
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